📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-15 14:34
417 analysed today
417
Today
136,937
All-time analysed
40,531
Positive
6,324
Negative
82,133
Neutral
7,881
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1 announcement match the current filters (relevance ≥ 5).
₹99.60 Cr Revenue in Q1 FY27; Chemkart Achieves ~50% of FY26 Revenue in Three Months
Chemkart India reported a robust start to FY27 with Q1 revenue reaching ₹99.60 crore, nearly 50% of the total revenue generated in the entire previous financial year. The company is aggressively transitioning from a distributor to an integrated manufacturer, with its EZRM facility completing plinth-level construction for Unit-1. Additionally, its subsidiary Vinstar Biotech has secured trial orders for in-house developed value-added ingredients, validating its R&D capabilities. The company added 15 key customers and currently has 20 R&D projects in the pipeline.
Confidence: HIGH
What changedChemkart has demonstrated a significant scale-up in its distribution revenue while reaching critical construction milestones for its first manufacturing plant.
Why it mattersThe transition from a pure distributor to an integrated manufacturer with proprietary R&D is a structural shift that typically leads to higher margins and stronger customer stickiness.
Revenue (Q1 FY27): ₹99.60 croreRevenue vs FY26 Full Year: ~50%New Customers Added: 15R&D Projects in Pipeline: 20India Nutraceutical CAGR (2026-30): 10.5%
📅 Short termThe strong revenue run-rate and tangible progress on the manufacturing facility are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe successful integration of manufacturing and R&D capabilities could re-rate the company from a trading entity to a specialty ingredients player over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in commissioning the EZRM manufacturing facility on schedule
- Potential margin volatility during the transition phase
Key Highlights
Reported revenue of ₹99.60 crore for Apr-Jun FY27, representing nearly 50% of the previous full year's revenue.
Added 15 key customers and initiated 20 R&D projects in the pipeline during the quarter.
Completed plinth-level construction for Unit-1 of the EZRM manufacturing facility and received electricity sanction.
Subsidiary Vinstar Biotech received trial orders for proprietary value-added ingredients from multiple customers.
Targeting the Indian nutraceutical market projected to grow from $37-38 Bn in 2026 to $55-57 Bn by 2030.
👀 What to Watch
Investors should monitor the commissioning timeline of the EZRM manufacturing facility and the conversion of Vinstar Biotech's trial orders into recurring commercial contracts.
